Personalis, Inc. has signed a letter of intent with Mount Sinai Services, Inc. of Toronto to offer the Personalis Accuracy and Content Enhanced (ACE) sequencing and analysis technology for clinical diagnostic and research tumor molecular profile sequencing and analysis and immuno-oncology sequencing in Canada.
The ACE Platform incorporates proprietary sample prep and sequencing processes that produce high levels of gene finishing and coverage of difficult-to-sequence regions.
Personalis currently provides comprehensive genomic testing for tumor-profiling through its ACE CancerPlus test for solid tumors. That test combines both DNA and RNA sequencing of more than 1,400 genes, and test results produce comprehensive tumor genomic profile data to guide therapy and ongoing research.
The ACE assays and informatics platform achieves coverage and sensitivity enabling variants to be identified more accurately and reliably in regions that may be completely missed by typical exomes, transcriptomes, and panels. The assays together with advanced informatics are CLIA validated to enable clinical diagnostic and clinical trials use.
“We are confident that our expertise in providing customized laboratory services, combined with the capabilities of the Personalis ACE Platform will contribute to advancing translational medicine by providing a comprehensive solution for pharma discovery and development of cancer therapies, and personalized clinical diagnostic cancer care,” Dr. Azar Azad, managing director of Mount Sinai Services, said.
Mount Sinai offers services, including medical device and diagnostic assay development and validation, in Canada.